Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

High fish intake tied to lower MS risk

Pearl Toh
19 May 2018

High intake of fish enriched with omega-3 polyunsaturated fatty acids (PUFAs) combined with fish oil supplements were associated with a lower risk of developing multiple sclerosis (MS), according to the MS Sunshine Study presented at the AAN 2018 Annual Meeting.

“High fish intake has been associated with a lower risk of MS but whether this is due to PUFAs or other nutrients is unclear [in previous studies],” said lead author Dr Annette Langer-Gould of Kaiser Permanente Southern California in Pasadena, California, US.

By analysing the changes in fatty acid desaturase (FADS) gene cluster that regulates the biosynthesis of PUFAs, the investigators also found evidence which suggests a protective role of omega-3 FAs against MS. 

The multi-ethnic, matched case-control MS Sunshine study followed 1,153 individuals on development of incident MS or its precursor known as clinically isolated syndrome (CIS). The participants were considered to have high fish intake if they reported consuming fish ≥1/week or 1–3 servings/month in addition to taking daily fish oil supplements. [AAN 2018, abstract 1826]

The risk of developing MS/CIS was 45 percent lower among participants with high fish intake compared with those who consumed fish less than once per month and who did not take fish oil supplements (adjusted odds ratio [OR], 0.55; p=0.0002).

Among the single nucleotide polymorphisms (SNPs) in FADS analysed, two SNPs in FAD2 — rs174611 and rs174618 — were independently associated with a reduced risk of MS, even after adjusting for high fish intake (ORs, 0.66; p= 0.007 and 0.64; p=0.016, respectively).

“These analyses support a protective role of fish consumption and PUFA biosynthesis on MS risk … [and] suggest that omega-3 FAs may play an important role in reducing MS risk,” the investigators said.

According to Langer-Gould, the findings add more evidence that a diet rich in fish is beneficial in relation to MS risk through its omega-3 content rather than a “substitution effect” — an effect seen because people were substituting fish for other food which are less healthy.

The researchers stressed that what the study reports is an association between high fish intake and reduced MS risk, and should not be extrapolated to imply a causal relationship.  

“Future studies to replicate our findings and determine whether [the protective role of fish intake on MS risk] is mediated by the anti-inflammatory, metabolic and/or neurological functions of PUFAs are needed,” they added.

 

 

Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.